Cargando…

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN

INTRODUCTION: MODERN (A4001095) was the first prospective phase 3 study comparing genotype vs phenotype (Trofile™) tropism assessments. MATERIALS AND METHODS: Treatment-naïve adults with HIV-1 RNA >1000 copies/mL were randomized 1:1 at screening to either genotype or Trofile for tropism assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heera, Jayvant, Valluri, Srinivas, Craig, Charles, Fang, Annie, Thomas, Neal, Meyer, Ralph Dan, Demarest, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Oral Presentation – Abstract O333
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224775/ https://www.ncbi.nlm.nih.gov/pubmed/25394028 http://dx.doi.org/10.7448/IAS.17.4.19519

Ejemplares similares

Implementation of a Chatbot Mobile Health Intervention with Home Spirometry to Monitor Lung Transplant Recipients Remotely
por: Odisho, A., et al.
Publicado: (2021)

Trends And Outcomes Of Heart Failure Hospitalizations During Covid 19 Pandemic In California
por: Chaparro, Sandra, et al.
Publicado: (2023)

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4(+) Cell Rises in HIV-Infected Patients
por: Funderburg, Nicholas, et al.
Publicado: (2010)

Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up
por: Violari, A, et al.
Publicado: (2012)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
por: Furtado, JJD, et al.
Publicado: (2010)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

A7 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba: Implications for pathogenesis and Maraviroc resistance
por: Méndez, M, et al.
Publicado: (2019)

ASP.NET MVC in action: with MvcContrib, NHibernate, and more
por: Palermo, Jeffrey, et al.
Publicado: (2010)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients
por: Oddershede, Lars, et al.
Publicado: (2014)

Life after the MVC
por: Tzovanakis, Harris
Publicado: (2017)

Pro PHP MVC
por: Pitt, Chris
Publicado: (2012)

Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
por: Cashin, Kieran, et al.
Publicado: (2015)

ASP.NET Core MVC 2.0 cookbook: effective ways to build modern, interactive web applications with ASP.NET Core MVC 2.0
por: Polat, Engin, et al.
Publicado: (2018)

Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype
por: Swenson, LC, et al.
Publicado: (2010)

Learn ASP.NET MVC
por: Weil, Arnaud
Publicado: (2015)

Professional ASPNET MVC 3
por: Galloway, Jon, et al.
Publicado: (2011)

When to start: as soon as possible
por: Saag, M
Publicado: (2012)

When to start: not so fast
por: Lundgren, J
Publicado: (2012)

Late presenters: what can we do?
por: Mussini, C
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h5qu0r9t35pich2oe6fgefhq3f